Matches in Ubergraph for { <https://frink.apps.renci.org/.well-known/genid/B6c1db7a3e23f909388ba80430dd2d3e9> ?p ?o ?g. }
Showing items 1 to 5 of
5
with 100 items per page.
- B6c1db7a3e23f909388ba80430dd2d3e9 NCIT_P378 "NCI" @default.
- B6c1db7a3e23f909388ba80430dd2d3e9 type Axiom @default.
- B6c1db7a3e23f909388ba80430dd2d3e9 annotatedProperty IAO_0000115 @default.
- B6c1db7a3e23f909388ba80430dd2d3e9 annotatedSource NCIT_C104292 @default.
- B6c1db7a3e23f909388ba80430dd2d3e9 annotatedTarget "An orally bioavailable inhibitor of phosphoinositide 3-kinase (PI3K), mammalian target of rapamycin (mTOR), activin receptor-like kinase 1 (ALK-1) and DNA-dependent protein kinase (DNA-PK), with potential anti-angiogenic and antineoplastic activities. Upon oral administration, panulisib inhibits the activity of all four kinases. This prevents PI3K/mTOR and ALK-1-mediated signaling pathways and may lead to the inhibition of cancer cell growth in PI3K/mTOR-overexpressing tumor cells and angiogenesis in ALK-1-overexpressing endothelial cells. Also, by inhibiting DNA-PK, this agent inhibits the ability of tumor cells to repair damaged DNA. The PI3K/mTOR pathway is upregulated in a variety of tumors and plays an important role in regulating cancer cell proliferation, growth, and survival. ALK-1, a member of the transforming growth factor beta (TGF-b) type I receptor family, is overexpressed on endothelial cells in a variety of tumor types and increases endothelial cell proliferation and migration. DNA-PK is activated upon DNA damage and plays a key role in repairing double-stranded DNA breaks." @default.